Krystal Biotech Inc
Krystal Biotech, Inc. Stock, NASDAQ:KRYS
Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.